A scoping review on emerging biomarkers in inflammatory bowel disease: Towards precision medicine in diagnosis and therapeutic management.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
da Silva Matheus Querino, Souza Menezes João Daniel de, Esteves Francisco José Luis, Michele da Silva Franciane, Rocha Paula Camile Vieira, de Oliveira Ruiz Paula Buck, Dos Santos Costa Caroline Cristina, de Amorin Laís Fernanda, Vaz Nunes Clarissa Albuquerque, de Almeida Neto Nilton Sebastião Garcia, Dos Santos Lorena Aline, Constancio Guilherme Ribeiro, Mendes Maira Ceruti, Bernardes da Rosa Ana Paula, Rondina Natália Ferreira, Cristovão Salvador André Bavaresco, Furlani Marcia Regina, de Sales Floriano Janaína Aparecida, Dos Santos Emerson Roberto, Júnior Fernando Nestor Facio, Spessoto Luís Cesar Fava, Ribeiro Rita de Cássia Helú Mendonça, Bianchin Maysa Alahmar, Ribeiro Filho Marco Antônio, Jericó Marli de Carvalho, Oliani Antônio Hélio, Oliani Denise Cristina Móz Vaz, Poletti Nádia Antônia Aparecida, Faria Mikaell Alexandre Gouvea, André Júlio César
Аннотация
METHODS: This scoping review synthesized recent findings on emerging biomarkers for IBD. We focused on technological advances in omics platforms (genomics, transcriptomics, proteomics, metabolomics, microbiomics), artificial intelligence, biosensors, and imaging techniques. Analysis identified biomarker potential for early diagnosis, disease activity monitoring, progression prognosis, and therapeutic response prediction. The review adhered to PRISMA-ScR guidelines and was registered with the Open Science Framework (OSF). The search encompassed five major databases: PubMed/MEDLINE, Scopus, Web of Science, Embase, and Google Scholar.
RESULTS: Studies demonstrate vast potential in non-invasive biomarkers for refined early diagnosis, optimized disease monitoring, and treatment response prediction. Key findings include metabolomic and gut microbiota profiles, genetic and epigenetic markers, and AI integration of complex data. These approaches promise to overcome conventional indicator limitations. From 784 initial records, 27 articles were included, published between 2021 and 2025.
CONCLUSION: Emerging biomarkers are fundamental for the transition to precision medicine in IBD. Their implementation aims to enhance pathogenesis understanding, personalize therapies, and improve patient quality of life, establishing pathways for more effective, individualized management approaches.